Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- July 31, 2018 Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
- July 24, 2018 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
- June 26, 2018 Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
- June 26, 2018 Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
- June 19, 2018 Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
- May 31, 2018 Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
- April 30, 2018 Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
- April 23, 2018 Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
- April 18, 2018 Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
- April 16, 2018 Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
Displaying 251 - 260 of 282